Radiation

Florida Homeowner Reaches Settlement in Phosphate Mining Radiation Case

Retrieved on: 
Wednesday, March 27, 2024
Chemicals, Plastics, Health, Legal, Manufacturing, Environmental Issues, Environmental Health, Residential Building & Real Estate, Commercial Building & Real Estate, Professional Services, Construction & Property, Oncology, Environment, Mining, Minerals, Natural Resources, Lymphoma, Risk, Radiation, Uranium, EPA, Cancer, Leukemia, Uranium mining

Drummond conducted phosphate mining for several years in the Central Florida region before developing the Oakbridge and Grasslands neighborhoods for commercial and residential use in the 1980s.

Key Points: 
  • Drummond conducted phosphate mining for several years in the Central Florida region before developing the Oakbridge and Grasslands neighborhoods for commercial and residential use in the 1980s.
  • Radiation from decaying uranium is a known byproduct of phosphate mining.
  • EPA testing before development of the subdivisions showed radiation levels 11 to 21 times higher than the acceptable risk limit.
  • In 2003, the EPA’s Florida Phosphate Initiative noted that some homes had median radiation concentrations four to 22 times higher than pre-mined land and gamma exposure two to three times higher than normal.

RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planning

Retrieved on: 
Thursday, March 28, 2024
Software, Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Oar, Algorithm, Noise, Risk, Patient, Reflection, Radiation, Outline, Radiation therapy, Neoplasm, Limbus, Multimedia, FDA, Medical imaging

RefleXion Medical , Inc., a therapeutic oncology company, and Limbus AI , Inc., a provider of software solutions for cancer radiation therapy, today announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.

Key Points: 
  • RefleXion Medical , Inc., a therapeutic oncology company, and Limbus AI , Inc., a provider of software solutions for cancer radiation therapy, today announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.
  • View the full release here: https://www.businesswire.com/news/home/20240327446154/en/
    Unedited head-and-neck image generated by the RefleXion® X1 displays excellent contrast and detail resolution, and near-perfect Limbus AI contours visible on several structures.
  • (Photo: Business Wire)
    “Contouring is one of the most time-consuming tasks in radiotherapy planning, and often contributes to treatment delays,” said Sam Mazin, Ph.D., co-founder and chief technology officer at RefleXion.
  • Both treatment modalities, biologic and anatomic, will benefit from the efficiencies of Limbus Contour integration.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Wednesday, March 27, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NMIBC, Research, Melanoma, Growth, Disease, SPA, Incidence, Paratriathlon, Inflammation, Patient, Necrosis, Travel, Light, Aes, American Academy, Cancer, Șaeș, Bladder cancer, Radiation, Eye, Doctor of Philosophy, MIBC, Visual acuity, Neoplasm, ILS, Aura, Safety, Recurrence, AAO, Annual general meeting, Food, Pharmaceutical industry

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
  • The primary endpoint is time to tumor progression when the last patient completes 15 months of follow up.
  • As of December 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $226.2 million.
  • General and administrative expenses include $1.2 million and $1.1 million of stock-based compensation for the three months ended December 31, 2023 and 2022, respectively.

Creative Medical Technology Holdings Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Health, FDA, General Health, Clinical Trials, Research, Science, Biotechnology, Consultant, Toxicity, Radiation, Medicine, Urology, Immunotherapy, T1D, Patient, History, IND, Regenerative medicine, Gynaecology, Investment, IP, Investigational New Drug, Clinical trial, Safety, Pain, Share repurchase, Endocrinology, Elective surgery, Food, IRB, Pharmaceutical industry

Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.

Key Points: 
  • Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
  • “In the past year our achievements have been some of the most consequential in the history of Creative Medical Technology,” said Timothy Warbington, the Company’s Chief Executive Officer.
  • We believe that our cell-based therapies have the potential to address critical unmet medical needs and are poised to pursue this objective.”
    He continued, “2023 was a year of significant achievement for Creative Medical, and our progress along multiple fronts has continued into 2024.
  • In Q1 2024, the Company announced the receipt of Orphan Drug Designation from the FDA for CELZ-101, or ImmCelz™.

Decision Sciences International Corporation Announces Breakthrough, Passive Human Detection Capability for Discovery®

Retrieved on: 
Monday, March 25, 2024
Technology, Other Defense, Security, Other Technology, Software, Government Technology, Hardware, Artificial Intelligence, Defense, Salt, Radiation, Machine learning, Muon, Customs, Steel, Total cost, Weapon, Coffee, Human, Lead, Radiation protection, Anomaly, TCO, Charged particle, NII, Multinational corporation, Water, Decision Sciences, Cargo scanning, Ice, Multimedia, Artificial intelligence, Medical imaging

DSIC’s passive Discovery® system does not generate any harmful radiation as does x-ray, and is intrinsically safe for the user, the cargo, and any human beings that may be hidden in the cargo.

Key Points: 
  • DSIC’s passive Discovery® system does not generate any harmful radiation as does x-ray, and is intrinsically safe for the user, the cargo, and any human beings that may be hidden in the cargo.
  • Now, in response to customer requirements, Decision Sciences has developed a new and revolutionary algorithm to safely detect human beings hidden inside containers and cargoes.
  • As Kevin Davies, DSIC’s Chief Commercial Officer stated: “This is a real game-changer in the fight against human trafficking globally.
  • As Discovery® is a totally passive system, no safety zone is needed, which significantly reduces the requirements for civil works radiation protection.

Fonon Highlights Its Titan FX Laser Cutting Systems for Applications in the Defense Industry

Retrieved on: 
Friday, March 22, 2024
Mobile, Wireless, Technology, Homeland Security, Defense, Government Technology, Military, Other Defense, Contracts, Public Policy, Government, Machine Tools, Metalworking & Metallurgy, Drones, Robotics, Security, Satellite, Photography, Other Manufacturing, Other Technology, Steel, Engineering, Networks, Hardware, Aerospace, Electronic Design Automation, Manufacturing, Radiation, Vibration, Titanium, Corporation, Light, Metal, Motion, Stainless steel, Nickel, Aircraft, FX, Aluminium, Ceramic

Fonon Corporation , a multi-market holding company, R&D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights applications for its laser cutting technologies for manufacturing in the defense industry.

Key Points: 
  • Fonon Corporation , a multi-market holding company, R&D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights applications for its laser cutting technologies for manufacturing in the defense industry.
  • Fonon is proud to serve manufacturers in the defense industry by offering its precision metal cutting solution, the Titan FX Laser Cutting System.
  • The Titan FX is a flatbed multipurpose fiber laser cutting system available in several sizes that offers a high-performance, cost-effective way to cut metals, including highly reflective metals.
  • The defense industry uses highly reflective metals across a multitude of applications, from transport and ballistics to protective gear components.

ICUS Endorses Expanded Role of Sonographers in CEUS Procedures

Retrieved on: 
Thursday, March 21, 2024
Other Health, Other Science, Pharmaceutical, Other Technology, Research, Oncology, Medical Devices, Hospitals, Genetics, Stem Cells, Science, Technology, Nursing, Cardiology, General Health, Biotechnology, Health, Health Technology, Diagnosis, Radiation, Brain, Organization, Contrast-enhanced ultrasound, UEA, IPhone, Thomas Jefferson University, CEUS, Diagnostic medical sonography, SDMS, Risk, Patient, ICUS, Echocardiography, Society, GE HealthCare, CME, Scope of practice, Google Images, Agent handling, Kidney, Definity, Android, Accreditation, Medical imaging

More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).

Key Points: 
  • More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).
  • “Sonographers play a vital role in conducting CEUS examinations, and continually learning new techniques, such as CEUS, is a core component of providing innovative care and elevating our profession,” said Maria Stanczak, a member of the ICUS board of directors who played a key role in updating CEUS content in the new Scope of Practice.
  • ICUS does not charge fees for membership, CME-accredited webinars on CEUS, newsletters and other CEUS resources or programming.
  • To join ICUS, register and learn more, visit the ICUS website at www.ICUS-Society.org , or download the free ICUS app for iPhone and Android devices.

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Radiation, Prostate cancer, AstraZeneca, Patient, RCS, Acquisition, Cancer, Actinium-225, PSMA, Investment, Antibody, VWAP, Peptide, Medical imaging

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Key Points: 
  • AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
  • These medicines deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules.
  • The acquisition brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca.
  • RCs combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Genetics, Research, Science, Biotechnology, ART, Radiation, SCC, Central Statistics Office (India), BWH, PNI, Risk, Patient, Journal, NCCN, Workflow, Dermatology, MPH, Recurrence, Metastasis, De-escalation, Medical imaging

Based on these gaps, the panel developed risk-based clinical recommendations and a workflow for ART referral in patients with SCC, which can be viewed in the JCAD article.

Key Points: 
  • Based on these gaps, the panel developed risk-based clinical recommendations and a workflow for ART referral in patients with SCC, which can be viewed in the JCAD article.
  • In nuanced discussions where the risks associated with ART may outweigh the benefits, the additional information provided by the DecisionDx-SCC test can assist in personalized decision-making.
  • The DecisionDx-SCC test can help radiation oncologists determine a more precise risk-benefit ratio for elective nodal radiation.
  • The panel recommended stronger consideration of elective nodal radiation for a DecisionDx-SCC Class 2B tumor, given the dramatically increased risk of nodal metastasis.

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
Monday, March 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.